Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA.

Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019.

2.

Development and applications of oncolytic Maraba virus vaccines.

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD.

Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Review.

3.

Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Walsh SR, Bastin D, Chen L, Nguyen A, Storbeck CJ, Lefebvre C, Stojdl D, Bramson JL, Bell JC, Wan Y.

J Clin Invest. 2018 Dec 18. pii: 121004. doi: 10.1172/JCI121004. [Epub ahead of print]

4.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD.

Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.

PMID:
29900060
5.

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy.

Allan KJ, Mahoney DJ, Baird SD, Lefebvre CA, Stojdl DF.

J Vis Exp. 2018 Apr 3;(134). doi: 10.3791/56913.

PMID:
29683442
6.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
7.

Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.

Balathasan L, Tang VA, Yadollahi B, Brun J, Labelle M, Lefebvre C, Swift SL, Stojdl DF.

Mol Ther Oncolytics. 2017 Sep 15;7:45-56. doi: 10.1016/j.omto.2017.09.004. eCollection 2017 Dec 15.

8.

Customized Viral Immunotherapy for HPV-Associated Cancer.

Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, Johnson-Obaseki S, Villeneuve PJ, Diallo JS, Dimitroulakos J, Wan Y, Lichty BD.

Cancer Immunol Res. 2017 Oct;5(10):847-859. doi: 10.1158/2326-6066.CIR-17-0102. Epub 2017 Sep 14.

9.

Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.

Tong JG, Valdes YR, Sivapragasam M, Barrett JW, Bell JC, Stojdl D, DiMattia GE, Shepherd TG.

BMC Cancer. 2017 Aug 30;17(1):594. doi: 10.1186/s12885-017-3600-2.

10.

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine.

Alkayyal AA, Tai LH, Kennedy MA, de Souza CT, Zhang J, Lefebvre C, Sahi S, Ananth AA, Mahmoud AB, Makrigiannis AP, Cron GO, Macdonald B, Marginean EC, Stojdl DF, Bell JC, Auer RC.

Cancer Immunol Res. 2017 Mar;5(3):211-221. doi: 10.1158/2326-6066.CIR-16-0162. Epub 2017 Feb 3.

11.

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.

Dobson CC, Naing T, Beug ST, Faye MD, Chabot J, St-Jean M, Walker DE, LaCasse EC, Stojdl DF, Korneluk RG, Holcik M.

Oncotarget. 2017 Jan 10;8(2):3495-3508. doi: 10.18632/oncotarget.13849.

12.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

13.

High-throughput screening to enhance oncolytic virus immunotherapy.

Allan KJ, Stojdl DF, Swift SL.

Oncolytic Virother. 2016 Apr 5;5:15-25. doi: 10.2147/OV.S66217. eCollection 2016. Review.

14.

Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy.

Swift SL, Stojdl DF.

Viruses. 2016 Feb 5;8(2). pii: E45. doi: 10.3390/v8020045. Review.

15.

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA, Stojdl DF, Lichty BD, Atkins H, Auer RC, Bell JC, Le Boeuf F.

J Control Release. 2015 Dec 28;220(Pt A):210-221. doi: 10.1016/j.jconrel.2015.10.030. Epub 2015 Oct 19.

PMID:
26482080
16.

Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein.

Courteau L, Crasto J, Hassanzadeh G, Baird SD, Hodgins J, Liwak-Muir U, Fung G, Luo H, Stojdl DF, Screaton RA, Holcik M.

Cell Death Dis. 2015 Aug 6;6:e1837. doi: 10.1038/cddis.2015.209.

17.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
18.

Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis.

Tong JG, Valdes YR, Barrett JW, Bell JC, Stojdl D, McFadden G, McCart JA, DiMattia GE, Shepherd TG.

Mol Ther Oncolytics. 2015 Sep 23;2:15013. doi: 10.1038/mto.2015.13. eCollection 2015.

19.

Virus therapy for cancer.

Mahoney DJ, Stojdl DF, Laird G.

Sci Am. 2014 Nov;311(5):54-9. No abstract available.

PMID:
25464663
20.

Going viral with cancer immunotherapy.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC.

Nat Rev Cancer. 2014 Aug;14(8):559-67. doi: 10.1038/nrc3770. Epub 2014 Jul 3. Review.

PMID:
24990523

Supplemental Content

Loading ...
Support Center